Log In
Print this Print this

ZFN Therapeutic for hemophilia A (SB-FVIII)

  Manage Alerts
Collapse Summary General Information
Company Sangamo BioSciences Inc.
DescriptionZinc finger DNA-binding protein nuclease (ZFN) targeting mutated Factor VIII
Molecular Target Factor VIII
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy
Latest Stage of DevelopmentPreclinical
Standard IndicationHemophilia
Indication DetailsTreat hemophilia A
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today